Contribute Try STAT+ Today

Hospitals participating in a federal drug discount program marked up cancer medicines four times for privately insured patients, and often charged cash-paying consumers the same as commercial insurers, a practice that does not “fit the mission” of serving low-income populations, a new analysis found.

Specifically, the median price charged for cancer treatments to commercial insurers or cash-paying patients was 3.8 times what was paid by 123 hospitals participating in the so-called 340B program. Moreover, the hospitals did not reduce prices charged to insurers or patients when their own purchase prices decline, according to the analysis by Moto Bioadvisors, a consulting firm.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment